These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25166888)

  • 1. From Science to Finance-A Tool for Deriving Economic Implications from the Results of Dietary Supplement Clinical Studies.
    Shanahan CJ; de Lorimier R
    J Diet Suppl; 2016; 13(1):16-34. PubMed ID: 25166888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The estimated costs and savings of medical nutrition therapy: the Medicare population.
    Sheils JF; Rubin R; Stapleton DC
    J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.
    Booth GL; Wang EE
    CMAJ; 2000 Jul; 163(1):21-9. PubMed ID: 10920726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model.
    Pradelli L; Eandi M; Povero M; Mayer K; Muscaritoli M; Heller AR; Fries-Schaffner E
    Clin Nutr; 2014 Oct; 33(5):785-92. PubMed ID: 24345520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based estimation of health care cost savings from the use of omega-3 supplementation among the elderly in Korea.
    Hwang JY; Kim WS; Jeong S; Kwon O
    Nutr Res Pract; 2015 Aug; 9(4):400-3. PubMed ID: 26244079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin B12 intramuscular injections versus oral supplements: a budget impact analysis.
    Masucci L; Goeree R
    Ont Health Technol Assess Ser; 2013; 13(24):1-24. PubMed ID: 24379898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of coronary heart disease and stroke: the case of Sweden.
    Zethraeus N; Molin T; Henriksson P; Jönsson B
    J Intern Med; 1999 Aug; 246(2):151-9. PubMed ID: 10447784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimates of the direct and indirect cost savings associated with heart disease that could be avoided through dietary change in the United States.
    Cawley J; Meyerhoefer C; Gillingham LG; Kris-Etherton P; Jones PJ
    J Med Econ; 2017 Feb; 20(2):182-192. PubMed ID: 27724055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supplemental calcium for the prevention of hip fracture: potential health-economic benefits.
    Bendich A; Leader S; Muhuri P
    Clin Ther; 1999 Jun; 21(6):1058-72. PubMed ID: 10440627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective].
    Klever-Deichert G; Hinzpeter B; Wendland G; Lauterbach K
    Med Klin (Munich); 2000 Jun; 95(6):305-13. PubMed ID: 10935414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated effects of reducing dietary saturated fat intake on the incidence and costs of coronary heart disease in the United States.
    Oster G; Thompson D
    J Am Diet Assoc; 1996 Feb; 96(2):127-31. PubMed ID: 8557937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapping the savings from vitamin-based prevention.
    Leader S; Mallick R
    Manag Care Interface; 1998 Oct; 11(10):95-9. PubMed ID: 10186011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study.
    Collins M; Mason H; O'Flaherty M; Guzman-Castillo M; Critchley J; Capewell S
    Value Health; 2014 Jul; 17(5):517-24. PubMed ID: 25128044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can a disease self-management program reduce health care costs? The case of older women with heart disease.
    Wheeler JR; Janz NK; Dodge JA
    Med Care; 2003 Jun; 41(6):706-15. PubMed ID: 12773836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of heart disease and risk behaviour: implications for expenditure on prevention.
    Kruse M; Davidsen M; Madsen M; Gyrd-Hansen D; Sørensen J
    Scand J Public Health; 2008 Nov; 36(8):850-6. PubMed ID: 19004902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events.
    Schmier JK; Rachman NJ; Halpern MT
    Manag Care; 2006 Apr; 15(4):43-50. PubMed ID: 16686171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Costs Associated with an Adequate Intake of Sugars, Salt and Saturated Fat in Germany: A Health Econometrical Analysis.
    Meier T; Senftleben K; Deumelandt P; Christen O; Riedel K; Langer M
    PLoS One; 2015; 10(9):e0135990. PubMed ID: 26352606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.